Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 2/20 | 0.60 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.60 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.60 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.60 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.60 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.60 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.48 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.48 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.48 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.48 |
| ▸ | ARG1 | P05089 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2783482 | 1.00 | GRIN2D (0.60) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL9179307 | 1.00 | GRIN2D (0.60) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL27150371 | 0.83 | GRIN2D (0.48) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL838859 | 0.83 | GRIN2D (0.48) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL8867563 | 0.81 | GRIA2 (0.64) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL2783303 | 0.81 | GRIA2 (0.64) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL20553364 | 0.81 | GRIA2 (0.64) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL839398 | 0.80 | GRIN2D (0.41) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL29089187 | 0.80 | GRIN2D (0.41) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL29089188 | 0.77 | GRIN2D (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150119327-A1 | DRUG SCREENING PLATFORM FOR RETT SYNDROME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-04-30 | — | — | US | claimed |
| US-12357635-B2 | Nanocarriers and their processing for diagnostics and therapeutics | RHODE ISLAND HOSPITAL (US) | 2025-07-15 | — | — | US | disclosed |
| EP-3551182-B1 | TOPICAL PHARMACEUTICAL COMPOSITION CONTAINING PHENYTOIN AND A (CO -)AN ALGESIC FOR THE TREATMENT OF CHRONIC PAIN | TOPICAL INNOVATIONS B V (NL) | 2025-03-19 | — | — | EP | disclosed |
| US-20240156853-A1 | IN VITRO AND IN VIVO INTRACELLULAR DELIVERY OF SIRNA VIA SELF-ASSEMBLED NANOPIECES | RHODE ISLAND HOSPITAL | 2024-05-16 | — | — | US | disclosed |
| US-11701379-B2 | In vitro and in vivo intracellular delivery of siRNA via self-assembled nanopieces | RHODE ISLAND HOSPITAL (US) | 2023-07-18 | — | — | US | disclosed |
| US-11147799-B2 | Topical pharmaceutical composition containing phenytoin and a (co-) analgesic for the treatment of chronic pain | Keppel Hesselink, Jan Marius (NL) | 2021-10-19 | — | — | US | disclosed |
| US-20210023117-A1 | IN VITRO AND IN VIVO INTRACELLULAR DELIVERY OF SIRNA VIA SELF-ASSEMBLED NANOPIECES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-01-28 | — | — | US | disclosed |
| US-20200375991-A1 | NANOCARRIERS AND THEIR PROCESSING FOR DIAGNOSTICS AND THERAPEUTICS | RHODE ISLAND HOSPITAL | 2020-12-03 | — | — | US | disclosed |
| US-20200069649-A1 | TOPICAL PHARMACEUTICAL COMPOSITION CONTAINING PHENYTOIN AND A (CO -) ANALGESIC FOR THE TREATMENT OF CHRONIC PAIN | TOPICAL INNOVATIONS B.V. (NL) | 2020-03-05 | — | — | US | disclosed |
| US-10555948-B2 | Nanocarriers and their processing for diagnostics and therapeutics | RHODE ISLAND HOSPITAL (US) | 2020-02-11 | — | — | US | disclosed |
| US-20100144868-A1 | Novel Neuroprotective Compounds and Uses Thereof | RAMOT AT AVIV UNIVERSITY LTD. (IL) | 2010-06-10 | — | — | US | disclosed |
| WO-2009155401-A1 | FORMULATIONS | NEUROSYSTEC CORPORATION (US) | 2009-12-23 | — | — | WO | disclosed |
| EP-1861104-A2 | IMPROVED GACYCLIDINE FORMULATIONS | Neurosystec Corporation (US) | 2007-12-05 | — | — | EP | disclosed |
| EP-1861161-A2 | APPARATUS AND METHOD FOR DELIVERING THERAPEUTIC AND/OR OTHER AGENTS TO THE INNER EAR AND TO OTHER TISSUES | Neurosystec Corporation (US) | 2007-12-05 | — | — | EP | disclosed |
| US-20060264897-A1 | Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues | NEUROSYSTEC CORPORATION (US) | 2006-11-23 | — | — | US | disclosed |
| US-20060205789-A1 | Gacyclidine formulations | NEUROSYSTEC CORPORATION (US) | 2006-09-14 | — | — | US | disclosed |
| WO-2006096518-A2 | IMPROVED GACYCLIDINE FORMULATIONS | NEUROSYSTEC CORPORATION (US) | 2006-09-14 | — | — | WO | disclosed |
| WO-2006079055-A2 | APPARATUS AND METHOD FOR DELIVERING THERAPEUTIC AND/OR OTHER AGENTS TO THE INNER EAR AND TO OTHER TISSUES | NEUROSYSTEC CORPORATION (US) | 2006-07-27 | — | — | WO | disclosed |
| US-5426114-A | Administering to treat dysfunction in excitatory amino acid neurotransmission | GUILFORD PHARMACEUTICALS INC. (US) | 1995-06-20 | — | — | US | disclosed |
| US-5331001-A | ω-[2-(tetrazolylalkyl)cyclohexyl]-2-aminoalkanoic acids as antagonists of excitatory amino acid receptors | GUILFORD PHARMACEUTICALS INC. (US) | 1994-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12357635-B2 | Nanocarriers and their processing for diagnostics and therapeutics | SYVN1, SSB, TNF | GRIN2D 4642/4885GRIN3B 3571/4885GRIN1 4102/4885 |
| US-11701379-B2 | In vitro and in vivo intracellular delivery of siRNA via self-assembled nanopieces | NFATC1, TRAF6, UACA | GRIN2D 4609/4885GRIN3B 4268/4885GRIN1 2951/4885 |
| US-20210023117-A1 | IN VITRO AND IN VIVO INTRACELLULAR DELIVERY OF SIRNA VIA SELF-ASSEMBLED NANOPIECES | NFATC1, TRAF6, UACA | GRIN2D 4609/4885GRIN3B 4268/4885GRIN1 2951/4885 |
| US-10555948-B2 | Nanocarriers and their processing for diagnostics and therapeutics | SYVN1, SSB, TNF | GRIN2D 4642/4885GRIN3B 3571/4885GRIN1 4102/4885 |
| US-20100144868-A1 | Novel Neuroprotective Compounds and Uses Thereof | GRM2, GRIN1, GRM3 | GRIN2D 36/4885GRIN3B 23/4885GRIN1 2/4885 |
| US-20150119327-A1 | DRUG SCREENING PLATFORM FOR RETT SYNDROME | GRIN2A, GRIN1, GRIN2B | GRIN2D 11/4885GRIN3B 12/4885GRIN1 2/4885 |
| US-20200375991-A1 | NANOCARRIERS AND THEIR PROCESSING FOR DIAGNOSTICS AND THERAPEUTICS | SYVN1, SSB, TNF | GRIN2D 4642/4885GRIN3B 3571/4885GRIN1 4102/4885 |
| US-20240156853-A1 | IN VITRO AND IN VIVO INTRACELLULAR DELIVERY OF SIRNA VIA SELF-ASSEMBLED NANOPIECES | NFATC1, TRAF6, UACA | GRIN2D 4609/4885GRIN3B 4268/4885GRIN1 2951/4885 |
| US-20060205789-A1 | Gacyclidine formulations | DCTD, TYMP, TYMS | GRIN2D 1007/4885GRIN3B 1332/4885GRIN1 1028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.